By Amara Osei

A single production barrel at Croma-Pharma's Austrian facility yields approximately 80,000 syringes of hyaluronic acid filler — and every one of them is inspected by hand before it ships. That figure comes from a rare press visit to the Vienna-area plant, where Obagi Medical brought a group of U.S. dermatologists, plastic surgeons and expert injectors to see how its newest FDA-approved fillers, MagIQ and ChIQ, are made.

Who makes MagIQ and ChIQ?

Croma-Pharma began in 1976, founded by two pharmacists in the back room of a Vienna pharmacy. "The pharmacy is still run by our founding family in the city center," said Valentin Gruber, director of global marketing and customer experience at Croma-Pharma. The company built its early expertise in pharmaceutical-grade hyaluronic acid for ophthalmology, including cataract surgery, and moved into aesthetic injectables manufacturing in 2009.

The MagIQ and ChIQ technology is not new globally. It has been sold for years outside the United States under Croma's Saypha portfolio. For Obagi, the partnership extends a skin-first brand into injectables. "We aim to build Obagi into a leading professional skin health company, and the partnership with MagIQ and ChIQ is an important step in expanding how we serve providers and consumers," said Drew Fine, U.S. general manager, professional channel at Obagi Medical.

What does the production line look like?

The plant runs a sealed filling system in which five needles work simultaneously, producing roughly 5,000 syringes an hour. Technicians reach the machinery only when something malfunctions, and even then they work through gloves built directly into the enclosed equipment.

Quality control extends to each individual unit:

• Every filled syringe — not a sample — is visually inspected by hand under a rotating, illuminated magnifier for defects such as cracks in the glass.
• Inspectors rotate off the task every 25 minutes to prevent eye fatigue.
• The line operates in a Class C–certified clean room, with the filling point engineered to Class A conditions, the highest standard of air cleanliness in pharmaceutical manufacturing.
• Air is continuously filtered and replaced throughout the line.

How rigorous is the testing?

Croma performs more than 21,000 tests a year, the company said, measuring everything from water purity to the exact force required to push gel through a needle. The quality-control lab tests finished product, raw materials, water and equipment before any batch is released. Every test generates documentation that regulators in some instances require the company to keep for up to 20 years.

The science behind the product also explains why fillers that look similar on paper can behave differently in an injector's hands. Croma's proprietary MACRO Core Technology brings hyaluronic acid chains to a more consistent length before they are cross-linked into a gel. "The composition is very distinct from other brands," said Konstantin Frank, MD, a Munich facial plastic surgeon who has worked with Croma for more than a decade. That consistency, he explained, lets the gel perform predictably from one treatment to the next.

What about complication fears?

Outside the lab, the physicians on the tour addressed the state of the filler market directly. "Complications are one of the main reasons why people are becoming afraid of hyaluronic acid fillers right now," Dr. Frank said. "But most of the time, it's not the fault of the HA; it's the wrong application of it."

The visit closed with a hands-on workshop where participants mixed raw hyaluronic acid into a gel themselves to see how composition influences stability, texture and performance. Before hydration, raw hyaluronic acid resembles wispy strands of cotton candy; after water, shaking and a vibration plate, it becomes a smooth, clear gel.

The next day, Dr. Frank demonstrated MagIQ and ChIQ in live patient treatments. His conclusion: the product is only part of the result. "You'll never get a great result if you only work on the structure, or on the surface. It needs to be in balance," he said.

For Obagi and Croma, the bet is that manufacturing transparency — 21,000 annual tests, hand-inspected syringes, Class A filling zones — will differentiate MagIQ and ChIQ in a U.S. filler market where the physician's technique, not the gel, drives most of the outcome.